Haidinger, Michael

Serum Amyloid A in Uremic HDL Promotes Inflammation

Weichhart, T., Kopecky, C., Kubicek, M., Haidinger, M., Döller, D., Katholnig, K., Suarna, C., Eller, P., Tölle, M., Gerner, C., et al. (2012) · Journal of the American Society of Nephrology

Dialysis and Renal Disease ManagementCholesterol and Lipid Metabolism

Cited by 201

Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells

Weichhart, T., Haidinger, M., Katholnig, K., Kopecky, C., Poglitsch, M., Lassnig, C., Rosner, M., Zlabinger, G. J., Hengstschläger, M., Müller, M., et al. (2011) · Blood

PI3K/AKT/mTOR signaling in cancerImmune Response and Inflammation

Cited by 141

Novel views on new-onset diabetes after transplantation: development, prevention and treatment

Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., et al. (2013) · Nephrology Dialysis Transplantation

Renal Transplantation Outcomes and TreatmentsPancreatic function and diabetes

Cited by 120

Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation–a randomized, double-blind, placebo-controlled trial

Haidinger, M., Werzowa, J., Hecking, M., Antlanger, M., Stemer, G., Pleiner, J., Kopecky, C., Kovarik, J. J., Döller, D., Pacini, G., et al. (2014) · American Journal of Transplantation

Diabetes Treatment and ManagementRenal Transplantation Outcomes and Treatments

Cited by 110

Vildagliptin and Pioglitazone in Patients With Impaired Glucose Tolerance After Kidney Transplantation: A Randomized, Placebo-Controlled Clinical Trial

Werzowa, J., Hecking, M., Haidinger, M., Lechner, F., Döller, D., Pacini, G., Stemer, G., Pleiner, J., Frantal, S., & Säemann, M. D. (2013) · Transplantation

Diabetes Treatment and ManagementRenal Transplantation Outcomes and Treatments

Cited by 87